Myelogenous Leukemia


Also found in: Dictionary, Thesaurus, Medical.

myelogenous leukemia

[‚mī·ə′läj·ə·nəs lü′kē·mē·ə]

Myelogenous Leukemia

 

(myelocytic leukemia, myeloid granulocytic leukemia, or myelosis), a disease of the blood system characterized by the overproduction of immature granulocytes (myelocytes, promyelocytes, less often myelo-blasts) in the hematopoietic organs.

In myelogenous leukemia, the number of leukocytes in the blood increases—in the initial period, up to 20,000 per micro-liter; in advanced stages, the number of leukocytes may reach 200,000 to 400,000 per microliter. Hemograms and myelograms show a predominance of cells of the granulocytic series (of varying degree of maturity: stab neutrophils, metamyelocytes, myelocytes, and promyelocytes). A distinguishing feature of these cells during myelogenous leukemia is change in the 21st and 22nd pairs of chromosomes. The percentage of basophils and eosinophils in the blood often increases, which indicates a more severe course of the disease. In the majority of cases there is an enlarged spleen. The disease progresses steadily. The terminal stage is characterized by emaciation, anemia, and the appearance of a large number of myeloblasts in the bone marrow and the blood.

Treatment includes chemotherapy, radiation therapy, general restorative therapy, and, when necessary, blood transfusion.

REFERENCE

Kassirskii, I. A., and G. A. Alekseev. Klinicheskaia gematologiia, 4th ed. Moscow, 1970.

A. M. POLIANSKAIA

References in periodicals archive ?
Pinkus, "T-cell blast crisis in chronic myelogenous leukemia: immunophenotypic and molecular biologic findings," American Journal of Clinical Pathology, vol.
DISCUSSION: Imatinib mesylate inhibits bcr-abl tyrosine kinase, Tyrosine kinase enzyme is regarded as the cause of Philadelphia chromosome--positive Chronic Myelogenous leukemia (CML), Gastrointestinal stromal tumors (GIST) (1-2) and other rare neoplasms (Dermatofibrosarcoma Protuberans) Imatinib (3-5) is used for treatment of CML in:
It is also investigated for additional indications, such as Myelodysplastic Syndrome (MDS) and Chronic Myelogenous Leukemia (CML).
Acute promyelocytic leukemia (APL) is a subtype of acute myelogenous leukemia (AML) by the French-American-British (FAB) classification characterized by the presence of malignant promyelocytes in the bone marrow and peripheral blood, t(15;17), a high incidence of disseminated intravascular coagulation (DIC), and a unique sensitivity to anthracyclines and all trans retinoic acid (ATRA) (1-2).
There are four major types of leukemia: acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and chronic lymphocytic leukemia (CLL).
"With the support of our partners, our employees and our customers, we hope to completely sell out of these totes by the end of April."Garay was diagnosed with chronic myelogenous leukemia in 2006.
John Montana, MD, 61, of acute myelogenous leukemia, September 29 in New York City.
About 10% of patients have their MDS transform into acute myelogenous leukemia.
Genzyme reports it is studying the use of the drug to improve efficacy of chemotherapy and/or immunotherapy in various types of hematologic malignancies such as chronic lymphocytic leukemia and acute myelogenous leukemia. In addition the company pursuing preclinical work to explore that role Maribel may play in cord blood transplantation, solid organ transplantation, cardiovascular diseases, renal ischemic disease, and a variety of additional types of solid tumor malignancies.
Vidaza was also shown to delay progression to acute myelogenous leukemia (AML) in patients with MDS.
Gastric carcinoma and other malignancies in patients with chronic myelogenous leukemia. Case report and review of the literature, with particular reference to young adults.
In patients with acute myelogenous leukemia (AML) undergoing a standard 7-day course of chemotherapy, positron emission tomography (PET) using the radiotracer fluoro-L-thymidine (FLT) performed after only one day of chemotherapy can indicate whether or not the patient is responding to treatment, according to a preliminary study.